At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 184 enrolled
Drug / intervention
Olaratumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Olaratumab, Nab-paclitaxel, and 2 other interventions for Metastatic Pancreatic Cancer. Completed, enrolled 184 participants across 34 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesGermany, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartJun 2017
Primary CompletionJan 2021
Study CompletionJun 2021
TodayJul 2026
First PostedMar 22, 2017
Enrollment StartJun 22, 2017
Primary CompletionJan 5, 2021
Study CompletionJun 17, 2021
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.3 years ago
Interventions
Olaratumabdrug
Administered IV
Nab-paclitaxeldrug
Administered IV
Gemcitabinedrug
Administered IV
Placebodrug
Administered IV